openPR Logo
Press release

Topoisomerase Drugs Pipeline Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Daiichi Sankyo, ImmunityBio, Monopar Therapeutics, Luye Pharma, Avacta, Tarveda Therapeutics, Cebiotex, Cybrexa

06-06-2023 12:36 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Topoisomerase Drugs

Topoisomerase Drugs

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Topoisomerase pipeline constitutes 60+ key companies continuously working towards developing 70+ Topoisomerase treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Topoisomerase Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Topoisomerase Market.
The Topoisomerase Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ https://www.delveinsight.com/report-store/topoisomerase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Topoisomerase Pipeline Report:
• Companies across the globe are diligently working toward developing novel Topoisomerase treatment therapies with a considerable amount of success over the years.
• Topoisomerase companies working in the treatment market are Daiichi Sankyo, ImmunityBio, Monopar Therapeutics, Luye Pharma, Avacta, Tarveda Therapeutics, Cebiotex, Cybrexa, and others, are developing therapies for the Topoisomerase treatment
• Emerging Topoisomerase therapies such as Datopotamab deruxtecan, Aldoxorubicin, Trastuzumab deruxtecan, Camsirubicin, LY 01610, AVA6000, PEN-866, CEB-01, CBX-12, and others are expected to have a significant impact on the Topoisomerase market in the coming years.

Topoisomerase Overview
The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme Inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. Development of new anti-topoisomerase drugs, e.g. may allow to limit the cardiotoxic effect of anthracyclines or reduce the incidence of drug-induced secondary cancers. After all, the growing importance and rapid development of molecular genetics and molecular biology may enable the use of anti-topoisomerase agents in personalised anticancer therapy.

Get a Free Sample PDF Report to know more about Topoisomerase Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/topoisomerase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Topoisomerase Route of Administration
Topoisomerase pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Topoisomerase Molecule Type
Topoisomerase Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Topoisomerase Pipeline Therapeutics Assessment
• Topoisomerase Assessment by Product Type
• Topoisomerase By Stage and Product Type
• Topoisomerase Assessment by Route of Administration
• Topoisomerase By Stage and Route of Administration
• Topoisomerase Assessment by Molecule Type
• Topoisomerase by Stage and Molecule Type

DelveInsight's Topoisomerase Report covers around 4+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Topoisomerase product details are provided in the report. Download the Topoisomerase pipeline report to learn more about the emerging Topoisomerase therapies- https://www.delveinsight.com/sample-request/topoisomerase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Topoisomerase Pipeline Analysis:
The Topoisomerase pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Topoisomerase with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Topoisomerase Treatment.
• Topoisomerase key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Topoisomerase Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Topoisomerase market.

Download Sample PDF Report to know more about Topoisomerase drugs and therapies- https://www.delveinsight.com/sample-request/topoisomerase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Topoisomerase Pipeline Drug Insight
• Coverage: Global
• Key Topoisomerase Companies: Daiichi Sankyo, ImmunityBio, Monopar Therapeutics, Luye Pharma, Avacta, Tarveda Therapeutics, Cebiotex, Cybrexa, and others.
• Key Topoisomerase Therapies: Datopotamab deruxtecan, Aldoxorubicin, Trastuzumab deruxtecan, Camsirubicin, LY 01610, AVA6000, PEN-866, CEB-01, CBX-12, and others.
• Topoisomerase Therapeutic Assessment: Topoisomerase current marketed and Topoisomerase emerging therapies
• Topoisomerase Market Dynamics: Topoisomerase market drivers and Topoisomerase market barriers

Request for Sample PDF Report for Topoisomerase Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/topoisomerase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1 Topoisomerase Report Introduction
2 Topoisomerase Executive Summary
3 Topoisomerase Overview
4 Topoisomerase- Analytical Perspective In-depth Commercial Assessment
5 Topoisomerase Pipeline Therapeutics
6 Topoisomerase Late Stage Products (Phase II/III)
7 Topoisomerase Mid Stage Products (Phase II)
8 Topoisomerase Early Stage Products (Phase I)
9 Topoisomerase Preclinical Stage Products
10 Topoisomerase Therapeutics Assessment
11 Topoisomerase Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Topoisomerase Companies
14 Topoisomerase Key Products
15 Topoisomerase Unmet Needs
16 Topoisomerase Market Drivers and Barriers
17 Topoisomerase Future Perspectives and Conclusion
18 Topoisomerase Analyst Views
19 Appendix
20 About DelveInsight

Trending Reports:
• Bronchial Spasm Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Bacterial Meningitis Market: https://www.delveinsight.com/report-store/bacterial-meningitis-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-epidemiology-forecast
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Thymic Carcinoma Market: https://www.delveinsight.com/report-store/thymic-carcinoma-market
• Bladder Cancer Market: https://www.delveinsight.com/report-store/bladder-cancer-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Helicobacter Pylori Infection Market: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market
• Intravenous Immunoglobulin Market: https://www.delveinsight.com/report-store/intravenous-immunoglobulin-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Pharmaceutical Consulting Companies: https://www.delveinsight.com/consulting
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/blog/androgenetic-alopecia-treatment-outlook
• Acute Lung Injury Market: https://www.delveinsight.com/report-store/acute-lung-injury-market
• Astigmatism Market: https://www.delveinsight.com/report-store/bacterial-meningitis-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market

Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Topoisomerase Drugs Pipeline Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Daiichi Sankyo, ImmunityBio, Monopar Therapeutics, Luye Pharma, Avacta, Tarveda Therapeutics, Cebiotex, Cybrexa here

News-ID: 3078991 • Views:

More Releases from DelveInsight Business Research

DelveInsight Unveils Strategic Case Study on Myopia Market Assessment & Forecast: Empowering Stakeholders with Precision Epidemiology and Competitive Market Intelligence
DelveInsight Unveils Strategic Case Study on Myopia Market Assessment & Forecast …
DelveInsight, a leading provider of healthcare market intelligence and strategic consulting services, has released an in-depth case study titled "Myopia Market Assessment & Forecast: A Case Study Analysis." This comprehensive assessment showcases how DelveInsight's multidisciplinary research framework enabled a global client to quantify pediatric myopia burden, evaluate treatment trends across emerging Asian economies, and identify untapped commercial potential in a rapidly expanding ophthalmic segment. With myopia prevalence rising at an alarming
DelveInsight Publishes Comprehensive Market & Competitive Assessment for the Cell Imaging Technology Domain to Support Strategic Commercial Decisions
DelveInsight Publishes Comprehensive Market & Competitive Assessment for the Cel …
[Albany, USA] - September 2025 - DelveInsight, a leading life sciences market research and consulting firm, announces the release of its latest market intelligence report, "Market & Competitive Assessment: Mapping Commercial Success in the Cell Imaging Technology Domain." This in-depth study offers a technical and data-driven evaluation of the global market for cell imaging and analysis devices, focusing on software-based systems including High-Content Screening (HCS) instruments, cell analyzers, and flow
Anaplastic Thyroid Cancer Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
Anaplastic Thyroid Cancer Pipeline 2025: Therapies Under Investigation, Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Anaplastic Thyroid Cancer pipeline constitutes 8+ key companies continuously working towards developing 8+ Anaplastic Thyroid Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Anaplastic Thyroid Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anaplastic Thyroid
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2025: MOA and ROA Insights, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Relapsed/Refractory Acute Myeloid Leukemia pipeline constitutes 50+ key companies continuously working towards developing 75+ Relapsed/Refractory Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across

All 5 Releases


More Releases for Topoisomerase

Evolving Market Drivers In The Topoisomerase I Inhibitors Industry: Surge In Can …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected Topoisomerase I Inhibitors Market Size During the Forecast Period? In recent times, the market size for topoisomerase I inhibitors has been experiencing robust growth. The market value, expected to mature from $5.18 billion in 2024 to $5.49 billion in 2025, suggests a compound annual growth rate (CAGR) of 6.2%. Factors
Topoisomerase Inhibitors Market to Exhibit a Remarkable CAGR of 5.10% by 2029, S …
Data Bridge Market Research analyses that the topoisomerase inhibitors will exhibit a CAGR of around 5.10% for the forecast period of 2022-2029. Growing demand for targeted mode of therapies, surge in the research and development activities for the development of novel drugs and therapies, increasing instances of cancer worldwide and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of topoisomerase inhibitors market. Market
Topoisomerase Inhibitors Market Size, Share, Growth, Global Trends Analysis by F …
Global Topoisomerase Inhibitors Market research document helps a lot to businesses by giving an insightful market data and information to businesses for making better decisions and defining business strategies. This report also studies the global Topoisomerase Inhibitors market status, competition landscape, market share, size, demands, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors. The Topoisomerase Inhibitors Market report is a perfect window to the Topoisomerase
Global Chemotherapy Market to Experience a Market Growth of CAGR 6.2% during the …
Chemotherapy, aka chemo, is a treatment procedure that is used to treat cancer by using anti-cancer drugs. The treatment aims to stop or kill the cancer cells as well as the fast-growing cells while causing the least possible damage to the normal cells. Considered as a systematic therapy, chemotherapy prevents the cancer cells from growing, dividing, and multiplying. The anti-cancer drugs travel through the bloodstream and helps to kill the
Top Key Players of Chemotherapy Market | Pfizer Inc., Eli Lilly & Company, ImClo …
According to the analysis offered by Market Research Future (MRFR), the global chemotherapy market has been presumed to strike a CAGR of 6.2% during the forecast period 2017 to 2023. Chemotherapy is an effective treatment for cancer which infuses drugs into the bloodstream to target specific cancer sites. The growth trajectory of the market is anticipated to be dominated by the rising burden of the disease. Chemotherapy is excessively used for
Chemotherapy Market Business Growth Statistics and Key Players Insights: Novarti …
Crystal Market Research has announced the addition of "Chemotherapy Market By Drugs (mitotic Inhibitors, Antimetabolites, Anti-tumor Antibiotics, Topoisomerase Inhibitors, Alkylating Agents, Topoisomerase Inhibitors), Route Of Administration (intravenous And Oral), Indication (lymphoma, Leukemia, Ovarian Cancer, Lung Cancer, Sarcoma, Myleoma, Breast Cancer) And End User (research Institutes And Hospitals) - Global Industry Analysis And Forecast To 2023" Market Research report to their database. Competitive Insights The leading players in the market are Eli Lilly